Trial reportLeukemia2018
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Abstract readClinical Trial, Phase III
In one paragraph
Trial report in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
9.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Targeted therapies in pediatric B-Cell acute lymphoblastic leukemia: mechanisms, efficacy, and future directions.Frontiers in pharmacology · 2026Pooled it
- Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.Current pharmaceutical design · 2024Pooled it
- Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review.PloS one · 2019Pooled it
- Trial
- A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.Blood advances · 2021Trial
- Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment.Frontiers in immunology · 2020Trial
- Trial
- Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations.Clinical pharmacokinetics · 2026Observational
- Article
- Article
- Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.Haematologica · 2026Article
- Dynamics ofHemaSphere · 2026Article
- Article
- Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia.Cancer reports (Hoboken, N.J.) · 2026Article
- An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.British journal of haematology · 2025Review
- [Identify the factors associated with treatment-free remission outcomes after imatinib discontinuation in children and adolescent patients with chronic myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- [How I treat pediatric chronic myeloid leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era.International journal of hematology · 2025Article
- Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations.British journal of haematology · 2025Article
- Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.British journal of haematology · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 20 institutions in 8 countries.
Meinolf SuttorpPediatric Hematology and Oncology, Department of Pediatrics, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany. meinolf.suttorp@uniklinikum-dresden.de.
Philipp SchulzeInstitute for Medical Informatics and Biometry, Faculty of Medicine "Carl Gustav Carus", TU Dresden, Dresden, Germany.
Ingmar GlaucheInstitute for Medical Informatics and Biometry, Faculty of Medicine "Carl Gustav Carus", TU Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0002-2524-1199
Gudrun GöhringDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Nils von NeuhoffDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Markus MetzlerPediatric Hematology and Oncology, University Children's Hospital, Erlangen, Germany.
Petr SedlacekPediatric Hematology and Oncology, Teaching Hospital Motol, 2nd Medical School, Charles University Motol, Prague, Czech Republic.
Eveline S J M de BontPediatric Hematology and Oncology, University Children's Hospital, Groningen, The Netherlands.
Adriana BalduzziPediatric Hematology and Hematopoietic Stem Cell Transplantation Unit, Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, Monza, Italy.
Birgitte LausenDepartment of Pediatric and Adolescent Medicine, University Hospital, Rigshospitalet, Copenhagen, Denmark.
Olga AleinikovaBelarus Research Center for Pediatric Oncology, Hematology, and Immunology, Minsk, Belarus.
Sabina SufliarskaDepartment of Pediatrics, BMT Unit, Comenius University Children's Hospital, Bratislava, Slovakia.
Günter HenzePediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
Gabriele StraussPediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
Angelika EggertPediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
Bernhard KremensDepartment of Pediatrics III, University Hospital, University of Duisburg-Essen, Duisberg, Germany.
Andreas H GrollPediatric Hematology and Oncology, University Children's Hospital, Münster, Germany.
Frank BertholdPediatric Hematology and Oncology, University Children's Hospital, Cologne, Germany.
Christoph KleinUniversity Children's Hospital, Ludwig Maximilians University, Munich, Germany.ORCID http://orcid.org/0000-0003-0956-0445
Ute Groß-WieltschPediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Karl Walter SykoraPaediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Arndt BorkhardtPediatric Hematology, Oncology, and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.ORCID http://orcid.org/0000-0002-6121-4737
Andreas E KulozikPediatric Oncology, Hematology, and Immunology, University Children's Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1953-0848
Martin SchrappePediatric Hematology and Oncology, University Children's Hospital, Kiel, Germany.
Christina NowaszPediatric Hematology and Oncology, Department of Pediatrics, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany.
Manuela KrumbholzPediatric Hematology and Oncology, University Children's Hospital, Erlangen, Germany.
Josephine T TauerPediatric Hematology and Oncology, Department of Pediatrics, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany.
Alexander ClaviezPediatric Hematology and Oncology, University Children's Hospital, Kiel, Germany.
Jochen HarbottOncogenetic Laboratory, Pediatric Hematology and Oncology, University Children's Hospital, Giessen, Germany.
Hans H KreipeInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Brigitte SchlegelbergerDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Christian ThiedeMedical Department I, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany.
Medizinische Hochschule Hannover · DEUniversity Hospital Carl Gustav Carus · DECharité - Universitätsmedizin Berlin · DEUniversitätsklinikum Erlangen · DEUniversity Hospital Schleswig-Holstein · DEZimmer Biomet (Germany) · DEBelarusian Research Center For Pediatric Oncology and Hematology · BYCharles University · CZComenius University Bratislava · SKHeidelberg University · DEHeinrich Heine University Düsseldorf · DEHelios Kliniken · DELudwig-Maximilians-Universität München · DEOlgahospital · DERigshospitalet · DKShriners Hospitals for Children - Canada · CAUniversity Children's Hospital Tübingen · DEUniversity Hospital Cologne · DEUniversity Hospital Münster · DEUniversity of Duisburg-Essen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m
Indexed as
AdolescentAntineoplastic AgentsBiomarkersBone MarrowChildChild, PreschoolCombined Modality TherapyDisease ProgressionFemaleHumansImatinib MesylateInfantLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleNeoplasm GradingNeoplasm StagingAntineoplastic AgentsBiomarkersImatinib MesylateProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.